Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPH NASDAQ:LEGN NASDAQ:PCVX NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$11.73+0.1%$11.94$6.55▼$13.54$1.54B1.251.65 million shs1,230 shsLEGNLegend Biotech$31.86+1.3%$35.11$27.34▼$51.77$5.80B0.231.29 million shs836,404 shsPCVXVaxcyte$42.52+3.2%$32.98$27.66▼$118.62$5.35B1.122.07 million shs1.92 million shsTGTXTG Therapeutics$36.750.0%$31.56$21.18▼$46.48$5.83B1.971.91 million shs1.53 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals+3.45%+5.97%-5.56%+39.57%+71.20%LEGNLegend Biotech-0.10%-3.68%-12.94%-20.40%-36.65%PCVXVaxcyte+1.60%+16.24%+26.80%+17.02%-61.40%TGTXTG Therapeutics-0.71%+1.02%+13.32%-3.74%+71.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$11.73+0.1%$11.94$6.55▼$13.54$1.54B1.251.65 million shs1,230 shsLEGNLegend Biotech$31.86+1.3%$35.11$27.34▼$51.77$5.80B0.231.29 million shs836,404 shsPCVXVaxcyte$42.52+3.2%$32.98$27.66▼$118.62$5.35B1.122.07 million shs1.92 million shsTGTXTG Therapeutics$36.750.0%$31.56$21.18▼$46.48$5.83B1.971.91 million shs1.53 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals+3.45%+5.97%-5.56%+39.57%+71.20%LEGNLegend Biotech-0.10%-3.68%-12.94%-20.40%-36.65%PCVXVaxcyte+1.60%+16.24%+26.80%+17.02%-61.40%TGTXTG Therapeutics-0.71%+1.02%+13.32%-3.74%+71.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 2.67Moderate Buy$13.0010.87% UpsideLEGNLegend Biotech 2.73Moderate Buy$69.50118.14% UpsidePCVXVaxcyte 2.75Moderate Buy$106.25149.91% UpsideTGTXTG Therapeutics 2.67Moderate Buy$49.0033.33% UpsideCurrent Analyst Ratings BreakdownLatest AUPH, LEGN, TGTX, and PCVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/7/2025LEGNLegend BiotechCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$40.0010/6/2025TGTXTG TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.0010/6/2025TGTXTG TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.009/27/2025AUPHAurinia PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025LEGNLegend BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PCVXVaxcyteWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025TGTXTG TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/17/2025TGTXTG TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$53.00 ➝ $55.009/12/2025PCVXVaxcyteThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$38.008/27/2025LEGNLegend BiotechCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$66.008/25/2025LEGNLegend BiotechJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$77.00 ➝ $78.00(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$235.13M6.56$0.32 per share36.70$2.68 per share4.38LEGNLegend Biotech$627.24M9.38N/AN/A$5.70 per share5.59PCVXVaxcyteN/AN/AN/AN/A$26.52 per shareN/ATGTXTG Therapeutics$329M17.72$0.12 per share306.43$1.43 per share25.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals$5.75M$0.4327.2720.94N/A23.31%20.06%13.81%11/6/2025 (Estimated)LEGNLegend Biotech-$177.03M-$0.88N/AN/AN/A-40.83%-32.00%-20.07%11/11/2025 (Estimated)PCVXVaxcyte-$463.93M-$4.11N/AN/AN/AN/A-16.85%-15.92%11/4/2025 (Estimated)TGTXTG Therapeutics$23.38M$0.3798.6536.75N/A13.31%26.05%9.58%11/3/2025 (Estimated)Latest AUPH, LEGN, TGTX, and PCVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/4/2025Q3 2025PCVXVaxcyte-$1.23N/AN/AN/AN/AN/A11/3/2025Q3 2025TGTXTG Therapeutics$0.24N/AN/AN/A$152.12 millionN/A8/11/2025Q2 2025LEGNLegend Biotech-$0.22-$0.34-$0.12-$0.34$237.49 million$255.06 million8/6/2025Q2 2025PCVXVaxcyte-$1.12-$1.22-$0.10-$1.22N/AN/A8/4/2025Q2 2025TGTXTG Therapeutics$0.32$0.17-$0.15$0.17$147.76 million$141.15 million7/31/2025Q2 2025AUPHAurinia Pharmaceuticals$0.17$0.16-$0.01$0.16$64.27 million$70.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.185.234.63LEGNLegend Biotech0.304.714.57PCVXVaxcyteN/A11.1111.11TGTXTG Therapeutics0.893.862.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%LEGNLegend Biotech70.89%PCVXVaxcyte96.78%TGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals12.20%LEGNLegend Biotech0.02%PCVXVaxcyte3.10%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300131.63 million115.57 millionOptionableLEGNLegend Biotech2,609184.57 million184.53 millionOptionablePCVXVaxcyte160129.82 million125.80 millionOptionableTGTXTG Therapeutics290158.67 million141.78 millionOptionableAUPH, LEGN, TGTX, and PCVX HeadlinesRecent News About These CompaniesAnalysts Offer Predictions for TG Therapeutics Q3 Earnings3 hours ago | marketbeat.comHC Wainwright Weighs in on TG Therapeutics FY2029 EarningsOctober 7 at 8:50 AM | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Raised to "Strong-Buy" at HC WainwrightOctober 7 at 8:00 AM | marketbeat.comTG Therapeutics assumed with a Buy at H.C. WainwrightOctober 6 at 12:57 PM | msn.comWhat TG Therapeutics (TGTX)'s Six-Year BRIUMVI Safety Data Means For ShareholdersOctober 4, 2025 | uk.finance.yahoo.comInstitutional investors are TG Therapeutics, Inc.'s (NASDAQ:TGTX) biggest bettors and were rewarded after last week's US$176m market cap gainOctober 4, 2025 | finance.yahoo.comTG announces updated data presentations from ULTIMATE I, II Phase 3 trialsSeptember 25, 2025 | msn.comTG Therapeutics, Inc.: New Data for BRIUMVI Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous ...September 24, 2025 | finanznachrichten.deTG Therapeutics Reports Six-Year Data for BRIUMVI® Showing Exceptional Efficacy and Consistent Safety Profile in Multiple Sclerosis TreatmentSeptember 24, 2025 | quiverquant.comQNew Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI TreatmentSeptember 24, 2025 | globenewswire.comWhat is B. Riley's Forecast for TG Therapeutics Q4 Earnings?September 20, 2025 | marketbeat.comStrs Ohio Makes New Investment in TG Therapeutics, Inc. $TGTXSeptember 20, 2025 | marketbeat.comWhat is B. Riley's Estimate for TG Therapeutics Q3 Earnings?September 19, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 18, 2025 | marketbeat.comB. Riley Forecasts Strong Price Appreciation for TG Therapeutics (NASDAQ:TGTX) StockSeptember 18, 2025 | marketbeat.comTG Therapeutics price target raised to $55 from $53 at B. RileySeptember 17, 2025 | msn.comTG Therapeutics, Inc. $TGTX Position Increased by Voya Investment Management LLCSeptember 17, 2025 | marketbeat.comGreat Lakes Advisors LLC Takes $401,000 Position in TG Therapeutics, Inc. $TGTXSeptember 15, 2025 | marketbeat.comIntech Investment Management LLC Grows Stock Holdings in TG Therapeutics, Inc. $TGTXSeptember 15, 2025 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Director Sagar Lonial Sells 20,852 SharesSeptember 14, 2025 | marketbeat.comUnited Services Automobile Association Purchases Shares of 8,531 TG Therapeutics, Inc. $TGTXSeptember 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAUPH, LEGN, TGTX, and PCVX Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$11.72 +0.02 (+0.13%) As of 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Legend Biotech NASDAQ:LEGN$31.86 +0.42 (+1.34%) As of 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Vaxcyte NASDAQ:PCVX$42.52 +1.31 (+3.17%) As of 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.TG Therapeutics NASDAQ:TGTX$36.75 -0.01 (-0.03%) As of 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End The Juice Is Loose: Why Plug Power's Rally Is Just the Beginning Joby's Stock Rallies as Public Flights Validate Global Game Plan SharkNinja Is Flashing a Buy Signal the Market Is Ignoring Why Semtech Stock Is Rallying After Its NVIDIA Setback Marvell Insiders Buy Shares—Should Investors Follow Suit? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
